[go: up one dir, main page]

WO2004056379A1 - Saponines et sapogenines a utiliser en combinaison avec une therapie anticancereuse - Google Patents

Saponines et sapogenines a utiliser en combinaison avec une therapie anticancereuse Download PDF

Info

Publication number
WO2004056379A1
WO2004056379A1 PCT/CA2003/001938 CA0301938W WO2004056379A1 WO 2004056379 A1 WO2004056379 A1 WO 2004056379A1 CA 0301938 W CA0301938 W CA 0301938W WO 2004056379 A1 WO2004056379 A1 WO 2004056379A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
composition
chemotherapeutic
cells
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/001938
Other languages
English (en)
Inventor
Dong Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panagin Pharmaceuticals Inc
Original Assignee
Panagin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panagin Pharmaceuticals Inc filed Critical Panagin Pharmaceuticals Inc
Priority to AU2003291896A priority Critical patent/AU2003291896A1/en
Publication of WO2004056379A1 publication Critical patent/WO2004056379A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Carmustine (N,N'-bis(2-hydroxyethyl)-N-nitrosourea or BCNU) is useful in the treatment of brain tumors (such as gliomas), multiple myeloma, Hodgkin's disease, non-Hodgkin's lymphoma and other malignant neoplasms.
  • sarcoma generally refers to a tumor which originates in connective tissue, such as muscle, bone, cartilage or fat, and is made up of a substance like embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance.
  • carcinomas that originate in cells that make organs which have glandular (secretory) properties or that originate in cells that line hollow viscera, such as the gastrointestinal tract or bronchial epithelia. Examples include, but are not limited to, adenocarcinomas of the breast, lung, pancreas and prostate.
  • compositions in combination with one or more chemotherapeutic agents may be used as part of a combination chemotherapy regimen to treat a subject having a multi-drug resistant (MDR) cancer.
  • MDR multi-drug resistant
  • the compositions may be used as chemosensitizing agents in order to enhance the inhibitory effects of a chemotherapeutic agent in the treatment of a subject having a MDR cancer.
  • Figure 3 demonstrates the enhanced effect of Composition 3 on human breast cancer cell MCF7.
  • 15 ⁇ g/mL of the composition killed 92% of cancer cells, while similar concentrations of Rh2, aPPT, or aPPD only killed 68%, 68%, and 69%, respectively.
  • the result is a much improved efficacy and potency compared to each individual component at concentrations that are the same as the total of the composition.
  • composition 4 does not cause irritation to the blood vessels.
  • Case 2 Female, 74 yr, Esophagus cancer (umbrella type), 6.0 cm long (x-ray image). Symptoms: difficulty in swallowing, pain, weight loss, frequent hiccups.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions comprenant au moins deux saponines et/ou sapogénines à utiliser en combinaison avec une thérapeutique dans le traitement contre le cancer. Ces compositions sont capables de chimio-sensibiliser des cellules aux effets d'agents chimiothérapeutiques. Cette invention concerne aussi des préparations pharmaceutiques et non pharmaceutiques comprenant une composition de cette invention à utiliser en combinaison avec des agents chimiothérapeutiques afin de chimio-sensibiliser des cellules cancéreuses aux effets de ces agents chimiothérapeutiques et des kits pharmaceutiques comprenant ces préparations.
PCT/CA2003/001938 2002-12-23 2003-12-23 Saponines et sapogenines a utiliser en combinaison avec une therapie anticancereuse Ceased WO2004056379A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003291896A AU2003291896A1 (en) 2002-12-23 2003-12-23 Saponins and sapogenins for use in combination therapy for cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43530502P 2002-12-23 2002-12-23
US60/435,305 2002-12-23

Publications (1)

Publication Number Publication Date
WO2004056379A1 true WO2004056379A1 (fr) 2004-07-08

Family

ID=32682215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001938 Ceased WO2004056379A1 (fr) 2002-12-23 2003-12-23 Saponines et sapogenines a utiliser en combinaison avec une therapie anticancereuse

Country Status (2)

Country Link
AU (1) AU2003291896A1 (fr)
WO (1) WO2004056379A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178802A1 (fr) * 2013-04-29 2014-11-06 Alkoçlar Redal Can Composition de protopanaxtriol pour le traitement du cancer de la prostate et de l'hyperplasie prostatique bénigne
CN107073024A (zh) * 2015-05-06 2017-08-18 智能合成生物中心 含人参皂苷F1或Rg3作为有效成分的用于预防或治疗格列卫耐药性白血病的药学组合物
CN113082039A (zh) * 2021-03-30 2021-07-09 香港浸会大学深圳研究院 一种用于治疗索拉菲尼耐药肿瘤的组合物及其应用
EP4101438A1 (fr) * 2021-06-11 2022-12-14 RainCastle bio. Limited Traitement combiné d'un agent saponine et d'un agent anthelminitique contre le cancer
WO2024046246A1 (fr) * 2022-08-29 2024-03-07 石药集团中奇制药技术（石家庄）有限公司 Utilisation de liposome de mitoxantrone en combinaison avec de la capécitabine dans le traitement du carcinome nasopharyngé

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58131999A (ja) * 1982-01-30 1983-08-06 Osaka Chem Lab 抗腫瘍剤
JPH059123A (ja) * 1991-07-01 1993-01-19 Isao Kitagawa 制癌剤
CN1128147A (zh) * 1994-03-28 1996-08-07 广东医学院 一种治疗肿瘤的新的提取物及其制剂和制法
CA2307393A1 (fr) * 2000-05-01 2001-11-01 The University Of British Columbia Chimiotherapie par administration d'un ginsenoside
WO2001082908A2 (fr) * 2000-05-01 2001-11-08 The University Of British Columbia Chimiotherapie basee sur l'utilisation de ginsenosides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58131999A (ja) * 1982-01-30 1983-08-06 Osaka Chem Lab 抗腫瘍剤
JPH059123A (ja) * 1991-07-01 1993-01-19 Isao Kitagawa 制癌剤
CN1128147A (zh) * 1994-03-28 1996-08-07 广东医学院 一种治疗肿瘤的新的提取物及其制剂和制法
CA2307393A1 (fr) * 2000-05-01 2001-11-01 The University Of British Columbia Chimiotherapie par administration d'un ginsenoside
WO2001082908A2 (fr) * 2000-05-01 2001-11-08 The University Of British Columbia Chimiotherapie basee sur l'utilisation de ginsenosides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199750, Derwent World Patents Index; Class B04, AN 1997-536811, XP002280790 *
HASEGAWA H ET AL: "REVERSAL OF DAUNOMYCIN AND VINBLASTINE RESISTANCE IN MULTIDRUG-RESISTANT P388 LEUKEMIA IN VITRO THROUGH ENHANCED CYTOTOXICITY BY TRITERPENOIDS", PLANTA MEDICA, THIEME, STUTTGART, DE, vol. 61, no. 5, October 1995 (1995-10-01), pages 409 - 413, XP001119242, ISSN: 0032-0943 *
JIA W ET AL: "Cytotoxicity and synergistic effect of Careseng on cancer cells", INTERNATIONAL JOURNAL OF CANCER. SUPPLEMENT, A.R. LISS, NEW YORK, NY, US, no. 13, 30 June 2002 (2002-06-30), pages 443, XP008029986, ISSN: 0898-6924 *
KIM H-E ET AL: "GINESONIDE RH-2 INDUCES APOPTOTIC CELL DEATH IN RAT C6 GLIOMA VIA A REACRTIVE OXYGEN- AND CASPASE-DEPENDENT BUT BCL-XL-INDEPENDENT PATHWAY", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 65, no. 3, 1999, pages PL33 - PL40, XP002255323, ISSN: 0024-3205 *
PARK J-D ET AL: "Effects of ginseng saponin on modulation of multidrug resistance", ARCHIVES OF PHARMACAL RESEARCH, NATL. FISHERIES UNIVERSITY, PUSAN, KR, vol. 19, no. 3, 1996, pages 213 - 218, XP008029987, ISSN: 0253-6269 *
PATENT ABSTRACTS OF JAPAN vol. 0072, no. 42 (C - 192) 27 October 1983 (1983-10-27) *
PATENT ABSTRACTS OF JAPAN vol. 0172, no. 70 (C - 1063) 26 May 1993 (1993-05-26) *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178802A1 (fr) * 2013-04-29 2014-11-06 Alkoçlar Redal Can Composition de protopanaxtriol pour le traitement du cancer de la prostate et de l'hyperplasie prostatique bénigne
CN107073024A (zh) * 2015-05-06 2017-08-18 智能合成生物中心 含人参皂苷F1或Rg3作为有效成分的用于预防或治疗格列卫耐药性白血病的药学组合物
EP3181137A4 (fr) * 2015-05-06 2018-02-28 Intelligent Synthetic Biology Center Composition pharmaceutique pour la prévention ou le traitement de la leucémie résistant au gleevec, contenant, comme principe actif, du ginsénoside f1 ou rg3
US10376530B2 (en) 2015-05-06 2019-08-13 Intelligent Synthetic Biology Center Pharmaceutical composition for preventing or treating gleevec-resistant leukemia containing ginsenoside F1 or ginsenoside Rg3 as an active ingredient
CN107073024B (zh) * 2015-05-06 2020-03-17 智能合成生物中心 含人参皂苷f1的用于预防或治疗格列卫耐药性白血病的药学组合物
CN113082039A (zh) * 2021-03-30 2021-07-09 香港浸会大学深圳研究院 一种用于治疗索拉菲尼耐药肿瘤的组合物及其应用
CN113082039B (zh) * 2021-03-30 2023-01-13 香港浸会大学深圳研究院 一种用于治疗索拉菲尼耐药肿瘤的组合物及其应用
EP4101438A1 (fr) * 2021-06-11 2022-12-14 RainCastle bio. Limited Traitement combiné d'un agent saponine et d'un agent anthelminitique contre le cancer
WO2022258838A1 (fr) * 2021-06-11 2022-12-15 Raincastle Bio. Limited Polythérapie à base d'un agent de saponine et d'un agent anthelmintique contre le cancer
WO2024046246A1 (fr) * 2022-08-29 2024-03-07 石药集团中奇制药技术（石家庄）有限公司 Utilisation de liposome de mitoxantrone en combinaison avec de la capécitabine dans le traitement du carcinome nasopharyngé

Also Published As

Publication number Publication date
AU2003291896A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
US20060013897A1 (en) Compositions for cancer therapy saponins or sapogenins
Amresh et al. Toxicological screening of traditional medicine Laghupatha (Cissampelos pareira) in experimental animals
Rahmatullah et al. Antihyperglycemic and antinociceptive activity evaluation of methanolic extract of whole plant of Amaranthus Tricolor L.(Amaranthaceae).
EP2182940A1 (fr) Utilisation de tétrahydrocannabinol et/ou du cannabidiol pour le traitement d'une maladie inflammatoire de l'intestin
Meral et al. Effects of Nigella sativa L. and Urtica dioica L. on selected mineral status and hematological values in CCl4-treated rats
US6187315B1 (en) Compositions and methods of treating cancer with tannin complexes
CN105920086A (zh) 一种补骨脂提取物的制备方法及补骨脂提取物
TW200400828A (en) A composition for cancer therapy
WO2004056379A1 (fr) Saponines et sapogenines a utiliser en combinaison avec une therapie anticancereuse
WO2004032947A1 (fr) Extrait ayant un action antitumoral et antitoxique
CN109731019B (zh) 一种具有化疗增效作用的组合物，包括组成、制备及应用
US7229652B2 (en) Extract from the leaves of Toona sinensis Roem., and the preparation process and uses thereof
EP1967193A1 (fr) Amélioration de thérapie anti-cancer par flavonoïdes
WO2004056372A1 (fr) Utilisation d'aglycon protopanaxadiol dans le traitement du cancer
CA2431806A1 (fr) Compositions pour la therapie anticancereuse
Lopa et al. Improved oral glucose tolerance with methanol extract of Musa textilis Nee and synergistic action with glibenclamide
US20040248986A1 (en) Use of n,n-diethyl-2-{-4-(phenylmethyl) - phenoxy} ethanamine monohydrochloride (dppe) in cancer therapy
WO2004056371A1 (fr) Utilisation d'aglycone protopanaxatriol dans la therapie du cancer
US11883452B2 (en) Use of combination or composition of Radix et Rhizoma Notoginseng and aspirin
CN105193869A (zh) 骨碎补及其提取物用于预防或治疗心衰的用途
Latha et al. A 90-DAY ORAL TOXICITY STUDY OF THE CHLOROFORM EXTRACT OF GOMPHRENA GLOBOSA IN RATS
CN104666779B (zh) 一种治疗非小细胞肺癌的药物及其制备方法
EP1005350A1 (fr) Composition et methode de traitement du cancer a l'aide de complexes d'acide tannique et de tanin
Adedoyin et al. The Effect of Ethanol Extract of Jatropha Tanjoresis on Haematological and Histopathological Properties of Phenyl Hydrazine Induced Anaemic Rat
Wandana et al. A Review of the Therapeutic Potential of Gymnema Sylvestre in Diabetes Management

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP